Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
exenatide · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| exenatide | ACTIVE_COMPARATOR | - |
| taspoglutide 10mg | EXPERIMENTAL | - |
| taspoglutide 10mg/20mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| exenatide | DRUG | 5mg twice daily for 4 weeks followed by 10mg twice daily |
| taspoglutide | DRUG | 10mg once weekly |
Inclusion Criteria: * adult patients, 18-75 years of age; * type 2 diabetes receiving metformin and/or pioglitazone or rosiglitazone for at least 12 weeks; * HbA1c \>=7.0% and \<=10% at screening; * BMI \>=25kg/m2 (\>23kg/m2 for Asians) and \<=45kg/m2 at screening; * stable weight +/- 5% for at lea...
Exenatide is used for the treatment of type 2 diabetes mellitus in patients inadequately controlled with metformin, thiazolidinedione, or a combination of both. It is being studied as an active comparator in a Phase 3 clinical trial.
Exenatide is being developed by Roche Holding AG, which trades under the ticker RHHBY. The drug is being evaluated in a Phase 3 clinical trial for type 2 diabetes mellitus.
Exenatide is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed.
Exenatide was studied in the completed Phase 3 trial NCT00717457, which enrolled 1189 patients with type 2 diabetes mellitus. The trial compared taspoglutide versus exenatide in patients inadequately controlled with metformin, thiazolidinedione, or both.
Exenatide is a small molecule being studied for type 2 diabetes mellitus. The specific molecular target is not disclosed in the available information, so its mechanism of action is not described here.